# NeuroOne Medical Technologies Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/NeuroOne Medical Technologies Corporation). ## Overview NeuroOne Medical Technologies develops and commercializes minimally invasive neurosurgical devices for diagnosing and treating brain and pain disorders. Its portfolio centers on FDA-cleared cortical and sEEG electrodes, radiofrequency ablation systems, and related electrode cable assemblies, with commercialization supported in part by a distribution agreement with Zimmer Biomet. ## Products & services • Evo Cortical electrodes for temporary brain recording, monitoring, and stimulation • Evo sEEG electrodes for subsurface brain recording and stimulation • OneRF Brain Ablation System for functional neurosurgical procedures • OneRF TN Ablation System for trigeminal neuralgia / facial pain • Electrode cable assembly products and related accessories • Development-stage products for epilepsy, Parkinson’s, pain, and drug delivery - **Diagnostic electrodes** (45%) — Cortical strip/grid and sEEG electrodes used to record and monitor brain activity in epilepsy and related disorders. - **Ablation systems** (35%) — Radiofrequency ablation products used for functional neurosurgery and pain-related lesioning. - **Electrode cable assemblies** (10%) — Supporting hardware and cable assemblies sold with the company’s electrode-based systems. - **Commercial collaboration revenue** (10%) — Milestone and other payments tied to the Zimmer distribution and commercialization arrangement. - Evo Cortical electrodes for temporary surface brain recording and stimulation - Evo sEEG electrodes for temporary subsurface brain recording and stimulation - OneRF Brain Ablation System for radiofrequency lesioning in nervous tissue - OneRF TN Ablation System for trigeminal neuralgia and facial pain - Electrode cable assembly products used with the company’s electrode systems - Pipeline products for epilepsy, Parkinson’s, pain management, and drug delivery ## Customers The company sells primarily to hospitals, neurosurgeons, and specialty medical centers that diagnose and treat epilepsy, Parkinson’s disease, trigeminal neuralgia, and chronic pain. Its products are used by clinicians who need minimally invasive tools for brain monitoring, lesioning, and stimulation, and by institutions that value FDA-cleared devices and reimbursement support. Zimmer Biomet is also a key commercial partner for distribution of selected brain products. - **Neurosurgery hospitals and epilepsy centers** (primary) — Buy cortical and sEEG electrodes for diagnosis and monitoring of epilepsy and other brain disorders. - **Pain management and functional neurosurgery providers** (primary) — Buy OneRF ablation systems for lesioning nerve tissue in pain and functional procedures. - **Distribution partner Zimmer Biomet** (primary) — Commercializes and distributes selected brain products, helping expand market access. - **Academic and clinical research institutions** (secondary) — Support development, evaluation, and early adoption of new electrode and ablation technologies. - Hospitals and neurosurgical centers performing epilepsy diagnostics and procedures - Neurosurgeons using cortical and sEEG electrodes for brain monitoring - Pain specialists treating trigeminal neuralgia and other nerve pain conditions - Academic and healthcare institutions involved in product development and adoption - Zimmer Biomet as a commercialization and distribution partner ## Geography NeuroOne is headquartered and operationally concentrated in the United States, where all employees are located and where current commercialization is centered. The company also states that its products compete in U.S. and international markets, but the disclosed operating footprint in the filings is overwhelmingly domestic. Geography matters because the business depends on U.S. FDA clearance, U.S. physician adoption, and compliance with U.S. healthcare transparency rules. - United States is the core operating base and employee location - Commercial activity is centered on U.S. FDA-cleared products - International competition exists, but disclosed operations are U.S.-centric - Physician transparency and compliance rules are a meaningful U.S. exposure - Future foreign expansion would add regulatory and reimbursement complexity ## Strategy The company’s strategy is to convert FDA clearances into broader commercial adoption across epilepsy, brain ablation, and pain indications. It is also extending the OneRF platform into trigeminal neuralgia and other pain markets while relying on Zimmer to help scale brain-product commercialization. Longer term, success depends on additional clearances, physician acceptance, and reimbursement support. - **Broaden commercialization of FDA-cleared products** (short-term) — Revenue depends on converting cleared devices into routine clinical use. - **Advance OneRF TN and other pipeline indications** (medium-term) — New indications can expand the addressable market beyond current products. - **Leverage Zimmer distribution** (short-term) — External commercialization support can accelerate market penetration and reduce sales burden. - Expand adoption of cleared cortical and sEEG electrode products - Use Zimmer to scale commercialization of brain-related products - Grow OneRF into trigeminal neuralgia and broader pain indications - Pursue additional FDA clearances to widen the addressable market - Build clinical relationships to support physician adoption and evidence generation ## Risks The business remains highly dependent on regulatory clearance, physician adoption, and successful commercialization of a small product set. It also faces execution risk from third-party manufacturing, reimbursement, competition from larger device companies, and reliance on Zimmer for brain-product distribution. Because the company is still loss-making and capital-intensive, financing and liquidity risk remain material. - **Failure to commercialize or gain market acceptance** [high] — Revenue is concentrated in a small set of neurosurgical products that must win physician adoption. - **Dependence on Zimmer for distribution** [high] — Zimmer has exclusive global rights for selected brain products, so execution by Zimmer directly affects sales. - **Manufacturing and supplier disruption** [medium] — Products rely on third-party contract manufacturers and outside suppliers, which can constrain output and margins. - **Regulatory and compliance burden** [medium] — Medical devices face FDA, GMP, and Sunshine Act requirements; failures can delay sales or trigger penalties. - **Capital and liquidity risk** [high] — The company has recurring losses and needs external funding to support development and commercialization. - Commercial adoption may lag due to entrenched competitor products and physician habits - Revenue depends on FDA clearances and successful expansion into new indications - Third-party manufacturing and supply disruptions can hurt margins and availability - Zimmer concentration creates dependence on a single commercialization partner - Losses and capital needs increase financing risk and dilution risk ## Accounting Revenue recognition is important because the company earns product revenue, license/collaboration revenue, and milestone-type payments under the Zimmer arrangement. Investors should also watch inventory and manufacturing cost judgments, royalty expense, and fair value accounting for warrants and other financing instruments, since these can materially affect reported results in a pre-profit medical device business. Loss carryforwards, stock-based compensation, and lease commitments also matter because they reflect the company’s capital-intensive stage and ongoing cash burn. - **Revenue recognition for product and collaboration revenue** — Can shift quarterly revenue and gross margin - **Inventory valuation and excess/obsolete reserves** — Affects cost of product revenue and gross profit - **Fair value of warrant liability** — Can create volatility in net income - **Royalty and license obligations** — Impacts gross margin and cash outflows - Product revenue is recognized on device sales and can be lumpy quarter to quarter - Zimmer collaboration and milestone payments affect license/collaboration revenue timing - Third-party manufacturing costs and inventory reserves affect gross margin - Warrant liability fair value can create non-cash earnings volatility - Stock-based compensation and financing costs are meaningful for a small public company --- *Last updated: 2026-04-28T20:28:36.646972+00:00*